Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy
Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy
复制标题
DOI：
10.1080/02841860500327503
复制
发表时间：
2005-10-01
期刊：
影响因子：
3.1
通讯作者：
Picci, P
中科院分区：
文献类型：
--
作者：
Bacci, G;Briccoli, A;Picci, P
报告了1986年至1998年在一家机构进行新辅助治疗后复发的235例肢体骨肉瘤患者的复发模式、治疗和最终结局。235例复发患者分别接受手术、手术加二线化疗、仅二线化疗或放疗治疗。5年无复发生存率（PREFS）为27.6%，总生存率（PROS）为28.7%。所有69例目前存活且无疾病的患者均接受手术治疗，单独或联合化疗。单纯化疗或放疗的患者无一存活。我们的结论是，这是可能的，以获得延长生存期和治愈约1/4的复发骨肉瘤患者的积极治疗。完全消除复发对预后至关重要，而二线化疗的联合作用仍有待确定。
The pattern of relapse, treatment and final outcome of 235 patients with osteosarcoma of the extremity who relapsed after neoadjuvant treatments performed between 1986 and 1998 at a single institution is reported. The 235 relapses were treated by surgery, surgery plus second line chemotherapy, and only second line chemotherapy or radiotherapy. The 5-year post-relapse-event-free- survival (PREFS) was 27.6% and the post-relapse-overall-survival ( PROS) 28.7%. All 69 patients who are presently alive and free of disease were treated by surgery, alone or combined with chemotherapy. None of patients treated only by chemotherapy or radiotherapy survived. We conclude that it is possible to obtain prolonged survival and cure in about 1/4 of relapsing osteosarcoma patients with aggressive treatments. The complete removal of the recurrence is essential for outcome, while the role of the association of second-line chemotherapy remains to be defined.